Roivant reports Phase 2b lupus failure for an FcRn drug

One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not improve symptoms by a ...